Retatrutide Pre-Mixed Pen 30mg

Retatrutide Triple Agonist (GLP-1 / GIP / Glucagon Receptor Agonist)

Retatrutide is a novel synthetic 39-amino acid peptide that functions as a triple hormone receptor agonist, simultaneously targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

Key Characteristics:

• Structure: Engineered peptide with lipidation for extended half-life and balanced agonism across three receptors

• Mechanism:

  • GLP-1 receptor activation → insulin secretion, appetite suppression, delayed gastric emptying

  • GIP receptor activation → enhanced insulin secretion and lipid metabolism

  • Glucagon receptor activation → increased energy expenditure, lipolysis, and hepatic fat oxidation

• Half-life: Approximately 6 days, supporting once-weekly dosing

Research Applications:

• Severe obesity and substantial weight loss studies

• Type 2 diabetes and glycemic control research

• Metabolic syndrome and insulin resistance models

• Non-alcoholic steatohepatitis (NASH) and liver fat reduction

• Body composition and lean mass preservation during weight loss

• Energy expenditure and lipid metabolism investigations

Retatrutide is currently one of the most advanced "triple agonist" candidates in metabolic research. By activating all three receptors (GLP-1 + GIP + Glucagon), it aims to achieve superior weight loss and metabolic benefits compared to dual agonists like tirzepatide, primarily through increased energy expenditure and enhanced fat oxidation while maintaining glycemic control.

For laboratory research use only. Not intended for human or veterinary use.